Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Supernus Pharmaceuticals

Nasdaq:SUPN
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SUPN
Nasdaq
$947M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Supernus Pharmaceuticals has significant price volatility in the past 3 months.
SUPN Share Price and Events
7 Day Returns
4.3%
NasdaqGM:SUPN
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-53.3%
NasdaqGM:SUPN
-2%
US Pharmaceuticals
-10%
US Market
SUPN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Supernus Pharmaceuticals (SUPN) 4.3% 13.1% -23.7% -53.3% -42.5% 33.7%
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • SUPN underperformed the Pharmaceuticals industry which returned -2% over the past year.
  • SUPN underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
SUPN
Industry
5yr Volatility vs Market

Value

 Is Supernus Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Supernus Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Supernus Pharmaceuticals.

NasdaqGM:SUPN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:SUPN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.65
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.646 (1 + (1- 21%) (39.95%))
0.9
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.9
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.9 * 5.44%)
6.63%

Discounted Cash Flow Calculation for NasdaqGM:SUPN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Supernus Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:SUPN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.63%)
2020 48.85 Analyst x2 45.81
2021 50.55 Analyst x2 44.46
2022 81.90 Analyst x2 67.55
2023 27.60 Analyst x1 21.35
2024 34.00 Analyst x1 24.66
2025 29.08 Est @ -14.47% 19.78
2026 26.28 Est @ -9.61% 16.77
2027 24.65 Est @ -6.2% 14.75
2028 23.71 Est @ -3.82% 13.30
2029 23.20 Est @ -2.15% 12.21
Present value of next 10 years cash flows $280.00
NasdaqGM:SUPN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $23.20 × (1 + 1.74%) ÷ (6.63% – 1.74%)
$482.36
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $482.36 ÷ (1 + 6.63%)10
$253.76
NasdaqGM:SUPN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $280.00 + $253.76
$533.76
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $533.76 / 52.53
$10.16
NasdaqGM:SUPN Discount to Share Price
Calculation Result
Value per share (USD) From above. $10.16
Current discount Discount to share price of $18.03
= -1 x ($18.03 - $10.16) / $10.16
-77.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Supernus Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Supernus Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Supernus Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SUPN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $2.16
NasdaqGM:SUPN Share Price ** NasdaqGM (2020-04-07) in USD $18.03
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Supernus Pharmaceuticals.

NasdaqGM:SUPN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SUPN Share Price ÷ EPS (both in USD)

= 18.03 ÷ 2.16

8.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Supernus Pharmaceuticals is good value based on earnings compared to the US Pharmaceuticals industry average.
  • Supernus Pharmaceuticals is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Supernus Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:SUPN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-17.3%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

NasdaqGM:SUPN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 8.36x ÷ -17.3%

-0.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Supernus Pharmaceuticals earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Supernus Pharmaceuticals's assets?
Raw Data
NasdaqGM:SUPN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $11.33
NasdaqGM:SUPN Share Price * NasdaqGM (2020-04-07) in USD $18.03
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:SUPN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SUPN Share Price ÷ Book Value per Share (both in USD)

= 18.03 ÷ 11.33

1.59x

* Primary Listing of Supernus Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Supernus Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Supernus Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Supernus Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Supernus Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-17.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Supernus Pharmaceuticals expected to grow at an attractive rate?
  • Supernus Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Supernus Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • Supernus Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SUPN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SUPN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -17.3%
NasdaqGM:SUPN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts -1.2%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SUPN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SUPN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 381 51 4
2023-12-31 319 8 5
2022-12-31 463 96 94 5
2021-12-31 418 69 68 5
2020-12-31 377 63 64 6
2020-04-08
NasdaqGM:SUPN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 393 143 113
2019-09-30 408 132 106
2019-06-30 409 157 105
2019-03-31 404 135 103
2018-12-31 409 129 111
2018-09-30 381 132 99
2018-06-30 359 109 87
2018-03-31 335 128 73
2017-12-31 302 115 57
2017-09-30 276 103 58
2017-06-30 253 92 104
2017-03-31 228 83 97

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Supernus Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Supernus Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SUPN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Supernus Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SUPN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.04 1.58 0.70 4.00
2023-12-31 0.37 1.32 -0.10 4.00
2022-12-31 1.67 2.45 1.25 4.00
2021-12-31 1.23 1.53 1.05 4.00
2020-12-31 1.19 1.37 1.05 5.00
2020-04-08
NasdaqGM:SUPN Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 2.16
2019-09-30 2.02
2019-06-30 2.01
2019-03-31 1.97
2018-12-31 2.13
2018-09-30 1.91
2018-06-30 1.69
2018-03-31 1.44
2017-12-31 1.13
2017-09-30 1.15
2017-06-30 2.08
2017-03-31 1.95

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Supernus Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Supernus Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Supernus Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Supernus Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Supernus Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Supernus Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Supernus Pharmaceuticals's 1-year earnings growth is less than its 5-year average (1.9% vs 37.1%)
  • Supernus Pharmaceuticals's earnings growth has exceeded the US Pharmaceuticals industry average in the past year (1.9% vs -0.2%).
Earnings and Revenue History
Supernus Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Supernus Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SUPN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 392.76 113.06 158.43 69.10
2019-09-30 408.24 105.82 164.75 65.15
2019-06-30 409.10 104.97 164.99 68.63
2019-03-31 403.94 102.98 164.01 71.70
2018-12-31 408.90 110.99 159.89 75.21
2018-09-30 381.40 98.76 151.60 75.54
2018-06-30 358.80 86.71 151.54 68.10
2018-03-31 335.09 73.34 146.52 58.88
2017-12-31 302.24 57.28 137.91 49.58
2017-09-30 276.18 57.95 133.20 46.66
2017-06-30 252.59 103.81 118.05 41.55
2017-03-31 228.39 96.69 109.09 41.83
2016-12-31 215.00 91.22 106.01 42.79
2016-09-30 196.32 83.75 100.52 38.98
2016-06-30 178.87 25.84 97.75 40.25
2016-03-31 162.92 18.03 94.82 36.01
2015-12-31 147.47 13.94 89.06 29.14
2015-09-30 135.01 10.88 83.55 25.46
2015-06-30 118.34 4.59 78.10 20.99
2015-03-31 112.34 5.36 74.49 18.79
2014-12-31 92.68 -10.93 72.61 19.59
2014-09-30 71.78 -37.12 69.78 19.22
2014-06-30 50.35 -58.84 66.95 18.34
2014-03-31 20.95 -89.40 59.58 17.21
2013-12-31 12.02 -92.27 55.59 17.25
2013-09-30 2.77 -83.38 49.05 16.99
2013-06-30 1.61 -72.77 38.51 21.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Supernus Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Supernus Pharmaceuticals used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • Supernus Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Supernus Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Supernus Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Supernus Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Supernus Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Supernus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Supernus Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Supernus Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Supernus Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:SUPN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 595.43 345.17 347.07
2019-09-30 557.26 341.16 296.70
2019-06-30 522.90 337.21 258.57
2019-03-31 480.02 333.31 292.94
2018-12-31 453.02 329.46 356.02
2018-09-30 421.94 325.67 280.23
2018-06-30 390.49 321.92 174.41
2018-03-31 351.87 318.23 489.73
2017-12-31 267.48 0.00 140.04
2017-09-30 251.66 0.00 114.55
2017-06-30 229.40 1.47 92.97
2017-03-31 206.06 3.31 87.13
2016-12-31 191.76 4.17 90.12
2016-09-30 173.37 5.77 80.33
2016-06-30 110.23 5.70 60.21
2016-03-31 97.11 5.63 45.26
2015-12-31 88.01 7.09 62.19
2015-09-30 109.44 8.07 57.70
2015-06-30 102.37 8.76 69.79
2015-03-31 94.58 11.71 64.84
2014-12-31 40.70 26.22 74.34
2014-09-30 66.12 26.50 72.56
2014-06-30 33.37 28.67 47.27
2014-03-31 29.01 28.36 58.87
2013-12-31 33.46 34.39 82.19
2013-09-30 12.45 60.18 87.24
2013-06-30 35.89 59.10 102.63
  • Supernus Pharmaceuticals's level of debt (58%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (63.1% vs 58% today).
  • Debt is well covered by operating cash flow (41.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 137.1x coverage).
X
Financial health checks
We assess Supernus Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Supernus Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Supernus Pharmaceuticals dividends.
If you bought $2,000 of Supernus Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Supernus Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Supernus Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SUPN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SUPN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Supernus Pharmaceuticals has not reported any payouts.
  • Unable to verify if Supernus Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Supernus Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Supernus Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Supernus Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Supernus Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Supernus Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Supernus Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jack Khattar
COMPENSATION $7,215,836
AGE 58
TENURE AS CEO 15.3 years
CEO Bio

Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has been its Chief Executive Officer, President, Secretary and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions during that time as a Board member, President and Chief Executive Officer of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. He has leadership, executive, managerial, business and pharmaceutical company experience, along with his more than 25 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies. From 1999 to 2004, he also served as a member of Shire plc's Executive Committee. Prior to that, Mr. Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA Labs Inc. (CIMA), a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khatta held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in various locations, including the United States, Europe and the Middle East. Mr. Khatta served on the Board of Rockville Economic Development, Inc. from 2003 to 2013. He serves on the Board of Directors of Prevacus, Inc., a privately-held development stage biotechnology company. Mr. Khatta has been Chairman of the Board of Directors of scPharmaceuticals Inc. since November 2017 and has been its Director since June 2016. Mr. Khatta earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.

CEO Compensation
  • Jack's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Jack's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Supernus Pharmaceuticals management team in years:

7.8
Average Tenure
64
Average Age
  • The average tenure for the Supernus Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jack Khattar

TITLE
Founder
COMPENSATION
$7M
AGE
58
TENURE
15.3 yrs

Gregory Patrick

TITLE
Senior VP & CFO
COMPENSATION
$1M
AGE
68
TENURE
8.4 yrs

Padmanabh Bhatt

TITLE
Chief Scientific Officer & Senior VP of Intellectual Property
COMPENSATION
$1M
AGE
62
TENURE
8.1 yrs

Stefan K. Schwabe

TITLE
Chief Medical Officer and Executive VP of Research & Development
COMPENSATION
$1M
AGE
67
TENURE
7.8 yrs

Todd Horich

TITLE
Vice President of Marketing
TENURE
5.3 yrs

Taylor Raiford

TITLE
Vice President of Sales
TENURE
5.3 yrs

Bryan Roecklein

TITLE
Vice President of Corporate Development
TENURE
4.8 yrs

Tami Martin

TITLE
Senior Vice President of Regulatory Affairs
AGE
64
Board of Directors Tenure

Average tenure and age of the Supernus Pharmaceuticals board of directors in years:

7.2
Average Tenure
66.5
Average Age
  • The tenure for the Supernus Pharmaceuticals board of directors is about average.
Board of Directors

Chuck Newhall

TITLE
Chairman of the Board
COMPENSATION
$298K
AGE
74
TENURE
3.7 yrs

Jack Khattar

TITLE
Founder
COMPENSATION
$7M
AGE
58
TENURE
15.3 yrs

Frederick Hudson

TITLE
Independent Director
COMPENSATION
$282K
AGE
74
TENURE
10.3 yrs

John Siebert

TITLE
Independent Director
COMPENSATION
$277K
AGE
79
TENURE
9.3 yrs

Georges Gemayel

TITLE
Independent Director
COMPENSATION
$267K
AGE
59
TENURE
5.1 yrs

Carrolee Barlow

TITLE
Independent Director
COMPENSATION
$365K
AGE
55
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Aug 19 Buy Jack Khattar Individual 23. Aug 19 23. Aug 19 7,200 $26.39 $189,982
X
Management checks
We assess Supernus Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Supernus Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Insider Buying: The Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Founder Just Bought US$190k Worth Of Shares

Check out our latest analysis for Supernus Pharmaceuticals The Last 12 Months Of Insider Transactions At Supernus Pharmaceuticals In fact, the recent purchase by Jack Khattar was the biggest purchase of Supernus Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. … Happily, the Supernus Pharmaceuticals insider decided to buy shares at close to current prices. … Insiders likely see value in Supernus Pharmaceuticals shares, given these transactions (along with notable insider ownership of the company).

Simply Wall St -

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Undervalued After Accounting For Its Future Growth?

See our latest analysis for Supernus Pharmaceuticals What can we expect from Supernus Pharmaceuticals in the future? … However, to properly examine the value of a high-growth stock such as Supernus Pharmaceuticals, we must reflect its earnings growth into the valuation. … So, when we include the growth factor in our analysis, Supernus Pharmaceuticals appears slightly overvalued , based on its fundamentals.

Simply Wall St -

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 37% Discount?

Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 10-year free cash flow (FCF) forecast 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Levered FCF ($, Millions) $150.4m $190.2m $270.6m $204.8m $166.8m $146.5m $135.2m $129.0m $125.9m $124.8m Growth Rate Estimate Source Analyst x4 Analyst x4 Analyst x3 Analyst x4 Est @ -18.58% Est @ -12.18% Est @ -7.71% Est @ -4.58% Est @ -2.39% Est @ -0.85% Present Value ($, Millions) Discounted @ 8.07% $139.2 $162.9 $214.4 $150.2 $113.1 $91.9 $78.5 $69.3 $62.6 $57.5 ("Est" = FCF growth rate estimated by Simply Wall St) Present Value of 10-year Cash Flow (PVCF)= $1.1b The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = US$125m × (1 + 2.7%) ÷ (8.1% – 2.7%) = US$2.4b Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = $US$2.4b ÷ ( 1 + 8.1%)10 = $1.11b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is $2.25b. … NasdaqGM:SUPN Intrinsic value, August 19th 2019 The assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows.

Simply Wall St -

What You Must Know About Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Beta Value

(NASDAQ:SUPN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … The fact that this is well above 1 indicates that its share price movements have shown sensitivity to overall market volatility. … What this means for you: Beta only tells us that the Supernus Pharmaceuticals share price is sensitive to broader market movements.

Simply Wall St -

Does Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) P/E Ratio Signal A Buying Opportunity?

Looking at earnings over the last twelve months, Supernus Pharmaceuticals has a P/E ratio of 16.44. … The formula for P/E is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for Supernus Pharmaceuticals: P/E of 16.44 = $32.43 ÷ $1.97 (Based on the year to March 2019.) Is A High Price-to-Earnings Ratio Good? … The Verdict On Supernus Pharmaceuticals's P/E Ratio Supernus Pharmaceuticals has a P/E of 16.4.

Simply Wall St -

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Immense Growth Potential?

View our latest analysis for Supernus Pharmaceuticals How will Supernus Pharmaceuticals perform in the near future? … I've plotted out each year's earnings expectations and inserted a line of best fit to calculate an annual growth rate from the slope in order to understand the overall trajectory of SUPN's earnings growth over these next few years. … NasdaqGM:SUPN Past and Future Earnings, July 17th 2019 By 2022, SUPN's earnings should reach US$245m, from current levels of US$111m, resulting in an annual growth rate of 17%.

Simply Wall St -

Should You Be Worried About Insider Transactions At Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)?

So we'll take a look at whether insiders have been buying or selling shares in Supernus Pharmaceuticals, Inc. … See our latest analysis for Supernus Pharmaceuticals Supernus Pharmaceuticals Insider Transactions Over The Last Year In the last twelve months, the biggest single sale by an insider was when the Chief Scientific Officer & Senior VP of Intellectual Property, Padmanabh Bhatt, sold US$263k worth of shares at a price of US$59.90 per share. … Insider Ownership of Supernus Pharmaceuticals Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own.

Simply Wall St -

You Might Like Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Do You Like Its Debt?

SUPN’s Debt (And Cash Flows) SUPN's debt levels surged from US$318m to US$364m over the last 12 months , which includes long-term debt. … On top of this, SUPN has produced US$135m in operating cash flow in the last twelve months, resulting in an operating cash to total debt ratio of 37%, meaning that SUPN’s operating cash is sufficient to cover its debt. … Next Steps: SUPN’s high cash coverage means that, although its debt levels are high, the company is able to utilise its borrowings efficiently in order to generate cash flow.

Simply Wall St -

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 32% Discount?

(NASDAQ:SUPN) by taking the expected future cash flows and discounting them to their present value. … A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) estimate 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $142.35 $162.16 $212.35 $284.82 $217.59 $178.58 $157.63 $145.98 $139.62 $136.51 Growth Rate Estimate Source Analyst x4 Analyst x5 Analyst x5 Analyst x4 Analyst x4 Est @ -17.93% Est @ -11.73% Est @ -7.39% Est @ -4.36% Est @ -2.23% Present Value ($, Millions) Discounted @ 7.69% $132.19 $139.83 $170.04 $211.79 $150.24 $114.50 $93.86 $80.71 $71.69 $65.08 Present Value of 10-year Cash Flow (PVCF)= $1.23b "Est" = FCF growth rate estimated by Simply Wall St After calculating the present value of future cash flows in the intial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. … NasdaqGM:SUPN Intrinsic value, May 20th 2019 Important assumptions We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows.

Simply Wall St -

Why Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Looks Like A Quality Company

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows Supernus Pharmaceuticals has a return on equity of 25% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Company Info

Description

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company’s product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

Details
Name: Supernus Pharmaceuticals, Inc.
SUPN
Exchange: NasdaqGM
Founded: 2005
$947,187,533
52,533,973
Website: http://www.supernus.com
Address: Supernus Pharmaceuticals, Inc.
1550 East Gude Drive,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SUPN Common Stock Nasdaq Global Market US USD 01. May 2012
DB S49 Common Stock Deutsche Boerse AG DE EUR 01. May 2012
LSE 0LB2 Common Stock London Stock Exchange GB USD 01. May 2012
BRSE S49 Common Stock Berne Stock Exchange CH CHF 01. May 2012
Number of employees
Current staff
Staff numbers
464
Supernus Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 09:10
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/02/28
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.